ChemoCentryx, Inc. (CCXI): Price and Financial Metrics

ChemoCentryx, Inc. (CCXI): $15.22

0.44 (+2.98%)

POWR Rating

Component Grades













Add CCXI to Watchlist
Sign Up

Industry: Biotech


of 500

in industry


  • CCXI scores best on the Value dimension, with a Value rank ahead of 67.57% of US stocks.
  • The strongest trend for CCXI is in Momentum, which has been heading down over the past 31 weeks.
  • CCXI ranks lowest in Momentum; there it ranks in the 5th percentile.

CCXI Stock Summary

  • With a year-over-year growth in debt of 183.68%, ChemoCentryx Inc's debt growth rate surpasses 94.45% of about US stocks.
  • Revenue growth over the past 12 months for ChemoCentryx Inc comes in at 104.79%, a number that bests 94.2% of the US stocks we're tracking.
  • The volatility of ChemoCentryx Inc's share price is greater than that of 96.71% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to ChemoCentryx Inc, a group of peers worth examining would be NKTR, DMRC, VUZI, RESN, and ZUO.
  • Visit CCXI's SEC page to see the company's official filings. To visit the company's web site, go to

CCXI Valuation Summary

  • In comparison to the median Healthcare stock, CCXI's price/sales ratio is 22.36% higher, now standing at 14.5.
  • CCXI's price/sales ratio has moved up 3.4 over the prior 115 months.
  • CCXI's price/earnings ratio has moved up 109.5 over the prior 115 months.

Below are key valuation metrics over time for CCXI.

Stock Date P/S P/B P/E EV/EBIT
CCXI 2021-01-22 63.1 11.0 -108.7 -115.7
CCXI 2020-01-27 66.8 38.3 -46.6 -48.3
CCXI 2018-08-06 6.4 21.1 37.2 35.0
CCXI 2013-06-03 86.0 5.3 -13.3 -13.0
CCXI 2012-12-12 12.3 3.3 -84.5 -97.4
CCXI 2012-11-30 13.6 3.6 -93.1 -107.5

CCXI Growth Metrics

  • Its 5 year price growth rate is now at 738.68%.
  • Its year over year net income to common stockholders growth rate is now at 2.83%.
  • The 3 year net income to common stockholders growth rate now stands at 19.87%.
Over the past 30 months, CCXI's revenue has gone down $20,608,000.

The table below shows CCXI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 69.236 -75.264 -63.38
2020-12-31 64.891 -81.143 -55.356
2020-09-30 70.58 -82.149 -41.008
2020-06-30 76.076 -82.726 -29.81
2020-03-31 33.809 -79.283 -65.227
2019-12-31 36.128 -70.123 -55.489

CCXI Price Target

For more insight on analysts targets of CCXI, see our CCXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.57 Average Broker Recommendation 1.75 (Moderate Buy)

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $15.22 52-week high $70.29
Prev. close $14.78 52-week low $9.53
Day low $14.80 Volume 202,267
Day high $15.24 Avg. volume 2,260,257
50-day MA $13.28 Dividend yield N/A
200-day MA $43.37 Market Cap 1.06B

ChemoCentryx, Inc. (CCXI) Company Bio

ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.

CCXI Latest News Stream

Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream

Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

2 Beaten-Down Biotech Stocks That Could Bounce Back

The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.

Yahoo | July 27, 2021

ChemoCentryx: CRL Less Likely

Bet_Noire/iStock via Getty Images In my previous coverage of ChemoCentryx (CCXI), I said that given the FDA’s critical briefing doc, a CRL was likely for ChemoCentryx. As published on Seeking Alpha, “Citing that the vote was more ‘50 / 50-ish,’ analyst Anupam Rama predicts a Complete Response Letter as the...

Avisol Capital Partners on Seeking Alpha | July 25, 2021

Hedge Funds Are Selling ChemoCentryx Inc (CCXI)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

Yahoo | July 21, 2021

Is Now the Time to Buy ChemoCentryx Stock?

Shares of the highly popular biotech stock ChemoCentryx (NASDAQ: CCXI) ticked up a few notches after a Wall Street analyst upgraded the stock to buy. Stifel analyst Dae Gon Ha thinks a recent development regarding the clinical-stage biotech's lead candidate is a pretty big deal that the rest of the stock market has mostly overlooked. Does recent receptivity from the Food and Drug Administration make ChemoCentryx a good stock to buy now, or is there another heartbreak on the horizon?

Yahoo | July 10, 2021

Chemocentryx: A Risky Yet Potentially Lucrative Bet

With shares sitting 73% into the red in 2021, it’s safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly been due to one event; in May, an FDA advisory committee expressed reservations regarding the application for avacopan, Chemocentryx’ treatment for anti-neutrophilic cytoplasmic autoantibody (ANCA)-vasculitis (AAV) – a rare disorder which can lead to inflammation and even destruction of small blood vessels.  On Tuesday, however, the company had some positive news concerning the drug.

Marty Shtrubel on TipRanks | July 9, 2021

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 15.48%
3-mo -42.85%
6-mo -75.78%
1-year -71.13%
3-year 38.74%
5-year 240.49%
YTD -75.42%
2020 56.56%
2019 262.51%
2018 83.36%
2017 -19.59%
2016 -8.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.934 seconds.